Mywyngil Therapeutics chases obesity drug without GLP-1 target

Mywyngil Therapeutics just raised seed funding to develop obesity drugs that don't target GLP-1. The startup is betting on a new mechanism to improve metabolic health beyond the current blockbuster drugs.